CYP1A2 and ADORA2A Genotypes and Endurance Performance.
NCT ID: NCT06547307
Last Updated: 2024-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2024-08-31
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Caffeine on Pain-Based Pacing During a Cycling Time-Trial
NCT02115763
Caffeine, CYPA12 and Resistance Exercise
NCT06610110
The Repeatability of the Effect of Caffeine Supplementation on Submaximal Physiological Responses and Cycling Time Trial Performance
NCT06935214
Caffeine, CYPA12 and Resistance Training
NCT06610123
The Effect of Caffeine in Elderly Citizens
NCT00117520
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will complete five visits (\~90-120 min each, 2 visits during the first week,3 visit during week 2-4) in the Laboratory at Faculty of Sports Studies of Masaryk University. All testing will take place Monday to Friday during morning hours (7-12) to minimize potential diurnal effect on sports performance. Participants will be instructed to maintain their regular diet (pre-testing meals will be replicated for all visits) and sleeping habits, avoid strenuous activity 48 hours before each visit, and abstain from caffeine one week prior to the first visit and for the duration of the data collection (4 weeks).
Sample size calculations We estimated sample size using G\*Power 3.1 (Version 3.1.9.4). Effect size = 0.25, the trial would be powered to detect small but still physiologically important effect.
Alpha error = 0.025 Power (1-Beta probability) = 0.8 Number of groups = 6 - number of stratification required for genotype subgroup analysis number of measurements = 3 Sample size = based on calculation, 60 participants are required
Recruitment
Recruitment will be carried out at Masaryk University by flyers. Recruitment will also take place online through sharing on the website and social networks of the Faculty of Sports Studies of Masaryk University.
Parameters of Assessment
Physiological data will be collected by a Ph.D.-level exercise physiologist and two doctoral students.
Height will be measured to the nearest 0.1 cm using a wall-mounted stadiometer, and body weight will be measured to the nearest 0.1 kg using a digital scale with participants wearing light clothing without shoes.
Body weight value will be measured on each visit and will be used to determine 2 and 4 mg per kilogram of body mass dosages for caffeine treatments (plus a placebo dose) that will be ingested in random order (derived by research assistant and blinded to all investigators) during visits 2, 3 and 4, over the following three weeks.
Body composition will be assessed by dual-energy x-ray absorptiometry (DXA; Horizon A, Hologic Inc. Marlborough, MA) during the first week of the study.
Exercise Tests
VO2max test
Each participant will initially perform an incremental exercise test. That test will assess Vo2max and maximal workload (Wmax), which is necessary for subsequent settings. Respiratory parameters will be measured breath-by-breath using a CORTEX METALYZER 3B. Wmax will be calculated using the following equation:
Wmax= Wfinal + (t/T) x Winc. Where Wfinal is the power output of the final completed stage, t is the time achieved in the final uncompleted stage (s), T is the duration of each stage (s) and Winc is the workload increment.
Time trial
The ergometer will be set to linear mode (workload increases as the pedalling rate increases). Each participant will perform a warm-up at 1 W/kg for 5 minutes. After the warm-up participants will be instructed to complete 10 km trial as quickly as possible (with no temporal, verbal, or physiological feedback). The primary variable measured will be the time to completion of the 10 km TT. The ergometer will be set to linear mode using the following formula:
W = L x (rpm)2, where rpm is the pedalling rate and L is a linear factor dependent on the participant's Wmax. To ensure consistency across participants, the resistance on the pedals during the TT will be set so that the participants would achieve 60 % of their power output at 80 rpm using the following equation:
L = (0.60 x Wmax)/6400
A familiarization time trial will occur during the first week of a study.
Rate of perceived exertion
During the time trial protocol, information about the rate of perceived exertion will be collected. Participants will be shown a Borgs scale of Perceived Exertion to assess the subject's fatigue, This will be performed twice during the time trial protocol (5th and 9th km)
Genotyping
Buccal mucosa smears will be collected during the first week of the study. Investigators will examine known genetic variations (CYP1a2 (rs 762551), ADORA2A (rs 5451876)) that are associated with caffeine metabolism and response, to determine if these genes affect response to exercise after subjects ingest caffeine.
Caffeine intake questionnaire
Investigators will use a Caffeine intake questionnaire - revised (CCQ-R) to determine habitual caffeine intake in the week before the study starts and then each week to discover whether the participants comply with the restriction regarding caffeine, or whether they have started consuming, for example, more chocolate
Training status
At the beginning of the study, participants with one of the study investigators will complete Training and Performance Caliber: A Participant Classification Framework, based on the study by McKay et al., 2021 to determine the training status of each individual.
Statistical analysis
The statistical analysis will be carried out using IBM SPSS software. Descriptive data will be reported (VO2max/peak, body height, body weight, %body fat, lean body mass, habitual caffeine intake, training status. A t-test will determine the comparison between genotypes. Potential differences between 10 km TT will be assessed by an ANOVA with treatment as a within-participants factor and genotype as a between-participants factor.if the distribution of the data will not be normal, we will apply non-parametric equivalent of the test
Experimental procedure
Week 1
There will be three visits to the laboratories of the Faculty of Sports Studies at Masaryk University (FSpS MU):
i. Participants will undergo body composition measurement (DXA) and a cheek swab for assessing selected gene variants. Data about height, weight and age will be collected (Day 1: approximate duration of visit to FSpS MU 60-90 minutes).
ii. Participants will undergo maximal load testing using a cycling ergometer test and critical power testing using a cycling ergometer test (Day 2: approximate duration of visit to FSpS MU 90 minutes).
iii. Participants will practice a 10-km time trial on the cycling ergometer (Day 3: approximate duration of visit to FSpS MU 60 minutes).
Weeks 2, 3, 4
Participants will undergo a 10-km time trial on the cycling ergometer. After arrival participants will be randomly assigned to one of the three conditions. They will always ingest same amount of the identical capsules (with same colour, size). After 50 minutes after the capsule ingestion, participants will start the warm-up and 60 minutes after the ingestion the TT will start. This procedure will be identical for all experimental week (2, 3 and 4). Participants may drink water ad libitum throughout the exercise test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Caffeine 2 mg
To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform one exercise test (10 km cycling time trial).
Caffeine 2 mg
To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
Caffeine 4 mg
To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform one exercise test (10 km cycling time trial).
Caffeine 4 mg
To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
Placebo
To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform one exercise test (10 km cycling time trial).
Caffeine 0 mg
To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Caffeine 2 mg
To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
Caffeine 4 mg
To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
Caffeine 0 mg
To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* any training status
* within age limits
* without contraindications to perform the test on a bicycle trainer
* No contraindications to caffeine intake
Exclusion Criteria
* Breast feeding
* Cardiovascular disease
* Hypertension
* Liver disease in the previous two months
* Taking drugs that can affect liver function
* Illness in the period of 14 days before the start of the research
* Use of caffeine during research
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Masaryk University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lucie Lipková
Role: PRINCIPAL_INVESTIGATOR
Masaryk University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Masaryk University
Brno, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MasarykU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.